Skip to main content
. Author manuscript; available in PMC: 2022 Aug 16.
Published in final edited form as: Metabolomics. 2021 Aug 16;17(9):74. doi: 10.1007/s11306-021-01822-2

Fig 3.

Fig 3

A) Concentrations of specific polar metabolites at baseline that are different between TCZ responders and non-responders measured by 1H-NMR before treatment with TCZ. These metabolites represent a group of potential biomarkers for predicting and assessing patient response to TCZ treatment. B) Concentrations of the same specific polar metabolites at baseline after dividing the non-responders between moderate-responder and non-responders at 6 months. SG3PC: Sn-glycero-3-phosphocholine. p values are shown in the graphics.